论文部分内容阅读
前列腺癌发病率呈逐年上升趋势,是威胁男性健康的重要疾病之一.前列腺癌疾病进程会经过多个发展阶段,不同阶段采用不同的治疗方式,但同一阶段患者对某种治疗的反应及其预后存在很大差异.前列腺特异性抗原(PSA)是前列腺癌诊疗过程中最常用的标记物,用于监测疾病和判断预后.由于PSA并不是前列腺癌特异性标记物,实际应用中有其局限性,而循环肿瘤细胞是恶性肿瘤释放入外周血中的,是血行转移的重要机制,它在外周血中的数量与多种恶性肿瘤的预后相关,其是否可以作为PSA的替代物之一在前列腺癌的诊疗中发挥作用值得探讨.本文将对循环肿瘤细胞在前列腺癌中的应用作一综述.“,”Prostate cancer has become one of the important diseases threatening the health of male patients,and its incidence has increased year by year.The history of prostate cancer consists of multiple stages and in each stage,various forms of treatments can be applied.However,the treatment response and prognosis vary among patients within the same stage.Prostate specific antigen (PSA),as the most common biomarker used to monitor disease progression and predict prognosis,has its own limitation because it is not prostate cancer-specific.Circulating tumor cell (CTC) is released by malignant tumors themselves and is one important mechanism leading hematogenous metastasis.The number of CTC is associated with the prognosis of several malignant tumors,but whether or not it can become one of the surrogates of PSA in prostate cancer remains controversial.This article will have a general review about the relationship between CTC and prostate cancer.